Related references
Note: Only part of the references are listed.Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas
Shingo Inaguma et al.
MODERN PATHOLOGY (2017)
Immunotherapy for colorectal cancer: where are we heading?
Debora Basile et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Sending family history questionnaires to patients before a colonoscopy improves genetic counseling for hereditary colorectal cancer
Koen Kessels et al.
JOURNAL OF DIGESTIVE DISEASES (2017)
Chinese consensus on the prevention of colorectal cancer (2016, Shanghai)
Jing-Yuan Fang et al.
JOURNAL OF DIGESTIVE DISEASES (2017)
An Expanding Role for Immunotherapy in Colorectal Cancer
Katherine M. Bever et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp
Y. Zhang et al.
ONCOGENE (2017)
PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation
Huanbin Wang et al.
ONCOIMMUNOLOGY (2017)
Targeting the PD-1 pathway: a new hope for gastrointestinal cancers
Burak Bilgin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Colorectal cancer statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages An Assessment of 245 Primary and 40 Metastatic Tumors
Erik A. Dill et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Aaron S. Mansfield et al.
CLINICAL CANCER RESEARCH (2016)
Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers
H. Wang et al.
ONCOGENE (2016)
Colonic mucosal N-methyl-D-aspartate receptor mediated visceral hypersensitivity in a mouse model of irritable bowel syndrome
Qing Qing Qi et al.
JOURNAL OF DIGESTIVE DISEASES (2016)
Oridonin derivative ameliorates experimental colitis by inhibiting activated T-cells and translocation of nuclear factor-kappa B
Qian Qian Liu et al.
JOURNAL OF DIGESTIVE DISEASES (2016)
Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease
Anthony Lopez et al.
JOURNAL OF DIGESTIVE DISEASES (2016)
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
Matthew W. Rosenbaum et al.
MODERN PATHOLOGY (2016)
Diet, microorganisms and their metabolites, and colon cancer
Stephen J. D. O'Keefe
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
Hiroyuki Inoue et al.
ONCOIMMUNOLOGY (2016)
Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
Zheng Wang et al.
OncoImmunology (2016)
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome
Joseph M. Obeid et al.
ONCOIMMUNOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo et al.
CELL (2015)
Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf et al.
NATURE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
Marcella Callea et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Anti program death-1/anti program death-ligand 1 in digestive cancers
Eleonore de Guillebon et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
ArhGAP30 promotes p53 acetylation and function in colorectal cancer
Jilin Wang et al.
NATURE COMMUNICATIONS (2014)
Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer
A. Murata et al.
BRITISH JOURNAL OF CANCER (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer
KR Mehta et al.
CLINICAL CANCER RESEARCH (2005)
Share Paper
